Skip to contentC
Cardiff Oncology, Inc.
C
CRDFCardiff Oncology, Inc. Q4 2017 · 10-K
Revenue$185.00K$185.00K+172.1% vs Q4 2016 Net Income-$2.57M-$2.57MderivedN/M vs Q4 2016 EPS Diluted-$0.06-$0.06N/M vs Q4 2016 The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Cardiff Oncology, Inc. · CIK 1213037 · Engraved from SEC EDGAR
-$3,784,277
N/M
Operating Cash Flowderived-$3,331,415N/M Free Cash Flowderived-$3,296,265N/M Margins · derivedOperating margin-2045.6%+12340.1 pt vs Q4 2016
Net margin-1388.9%+11181.2 pt vs Q4 2016
ended Dec 31, 2017 · filed Feb 26, 2018 · 57 d after period end